Acromegaly Treatment and Management

Acromegaly treatment focuses on lowering growth hormone levels. Learn about surgery, medications & radiation therapy options available at LIV  for effective management

Treatment and Management of Acromegaly

The treatment and management of acromegaly requires a coordinated approach that addresses excess growth hormone production, alleviates symptoms, and reduces long‑term health risks. This page is designed for patients diagnosed with acromegaly, their families, and referring physicians seeking clear guidance on therapeutic options available at Liv Hospital. With a prevalence of approximately 3–4 cases per million people worldwide, early intervention can dramatically improve quality of life and life expectancy. In the following sections we explore diagnostic pathways, medication regimens, surgical techniques, radiotherapy options, multidisciplinary follow‑up, and practical considerations for international patients traveling to Istanbul for care.

Liv Hospital’s endocrine team combines JCI‑accredited expertise with state‑of‑the‑art facilities, ensuring that every aspect of treatment and management is personalized, evidence‑based, and delivered with compassion. Whether you are evaluating first‑line medical therapy, planning minimally invasive surgery, or considering newer targeted agents, our specialists will guide you through each decision point.

Understanding Acromegaly: Causes and Diagnosis

Acromegaly is a rare hormonal disorder most commonly caused by a benign pituitary adenoma that secretes excess growth hormone (GH). Elevated GH stimulates the liver to produce insulin‑like growth factor‑1 (IGF‑1), leading to characteristic tissue overgrowth, metabolic disturbances, and organ enlargement. Early diagnosis hinges on recognizing subtle clinical signs—such as enlarging hands and feet, facial coarsening, and joint pain—combined with biochemical testing.

Key diagnostic steps include:

• Serum IGF‑1 measurement: Elevated levels confirm chronic GH excess.
• Oral glucose tolerance test (OGTT): Failure of GH to suppress below 1 ng/mL after glucose load is diagnostic.
• Magnetic resonance imaging (MRI): High‑resolution scans identify tumor size, invasiveness, and relationship to surrounding structures.

Accurate assessment of tumor size and invasiveness informs the subsequent treatment and management strategy, influencing the choice between medical therapy, surgery, or radiotherapy. Patients are also screened for comorbidities such as hypertension, type‑2 diabetes, sleep apnea, and cardiomyopathy, which may require concurrent management.

Medication‑Based Treatment and Management Strategies

Pharmacologic therapy is often the first line of treatment and management when surgery is contraindicated, incomplete, or as an adjunct to achieve biochemical control. The main drug classes include:

Surgical Options for Acromegaly

Surgery remains the cornerstone of curative treatment and management for many patients, particularly when the adenoma is well‑defined and accessible. The most common approach is transsphenoidal surgery (TSS), performed through the nasal cavity to reach the pituitary gland with minimal disruption of brain tissue.

Key advantages of transsphenoidal surgery include:

• High remission rates (≈70 % for microadenomas, 50 % for macroadenomas).
• Short hospital stay (typically 2–3 days).
• Reduced postoperative discomfort compared with craniotomy.

In cases where the tumor extends laterally into the cavernous sinus or is fibrous, a combined endoscopic‑microscopic technique or a staged craniotomy may be required. The following table contrasts the two primary surgical routes:

Radiotherapy and Emerging Therapies

When surgery and medication do not fully control GH excess, radiotherapy offers an additional modality for long‑term disease control. Conventional fractionated radiotherapy (FRT) delivers low‑dose radiation over several weeks, whereas stereotactic radiosurgery (SRS) such as Gamma Knife provides a high‑dose, single‑session treatment targeting the adenoma precisely.

Benefits and considerations include:

• Gradual reduction of GH/IGF‑1 over 2–5 years.
• High tumor control rates (>90 %).
• Potential delayed hypopituitarism, especially with FRT.
• SRS offers lower risk of hypopituitarism but is limited by tumor size (<3 cm).

Emerging therapies under investigation at leading centers involve molecular inhibitors targeting the GH‑GH receptor axis, such as tyrosine kinase inhibitors and novel peptide analogs. Clinical trials are available for eligible patients, providing access to cutting‑edge options that may become part of future treatment and management algorithms.

Multidisciplinary Care and Follow‑Up Planning

Acromegaly’s systemic impact necessitates a coordinated, multidisciplinary approach. At Liv Hospital, a dedicated endocrine team collaborates with neurosurgeons, radiation oncologists, cardiologists, sleep specialists, and nutritionists to deliver comprehensive care.

Core components of ongoing follow‑up include:

• Quarterly IGF‑1 and GH measurements during the first year, then semi‑annually.
• Annual MRI to monitor residual or recurrent tumor growth.
• Screening for cardiovascular disease, glucose intolerance, and sleep apnea.
• Patient education on symptom awareness and lifestyle modifications.

This structured surveillance ensures early detection of disease recurrence and timely adjustment of the treatment and management regimen. Telemedicine appointments are also available for international patients who require remote monitoring after returning to their home countries.

Preparing for Treatment as an International Patient

Liv Hospital’s 360‑degree international patient service streamlines every step of the journey, from initial consultation to post‑discharge follow‑up. The following checklist helps patients plan their visit efficiently:

• Medical Documentation: Obtain recent lab results, imaging studies, and medication lists in English.
• Visa & Travel: Secure a medical visa; the hospital’s concierge can provide invitation letters.
• Accommodation: Choose from partner hotels or hospital‑affiliated residences located near the campus.
• Interpreter Services: Professional medical interpreters are available at no extra cost.
• Transportation: Airport transfers and local transport can be arranged.
• Post‑Treatment Follow‑Up: Coordinate telehealth sessions and obtain electronic copies of discharge summaries.

By integrating these logistical elements with the clinical treatment and management plan, international patients experience a seamless, stress‑free pathway to optimal outcomes.

Why Choose Liv Hospital

Liv Hospital combines JCI accreditation, a multilingual care team, and cutting‑edge technology to deliver world‑class endocrine services. Our specialists have extensive experience treating acromegaly, and our dedicated international patient department ensures that every logistical need—from visa assistance to post‑treatment teleconsultations—is handled professionally. Patients benefit from personalized care plans, transparent communication, and a commitment to safety and excellence that aligns with global standards.

Ready to start your personalized journey toward effective acromegaly treatment and management? Contact Liv Hospital today to schedule a virtual consultation and discover how our expert team can support you from diagnosis through recovery.